| Literature DB >> 15158550 |
Boris Bentsianov1, Craig Zalvan, Andrew Blitzer.
Abstract
Since the introduction of botulinum toxin (BTX) as a therapeutic tool in the 1970s, the number of uses for this substance has increased exponentially. BTX's mechanism of action involves degrading the SNARE proteins blockading the release of acetylcholine into the neuromuscular junction. In many body systems, decrease of contractility, strength, and tension of certain muscle groups result in improved clinical outcomes. Applications now include cosmetic, gastroenterologic, otolaryngologic, genitourinary, neurologic, and dermatologic uses. In fact, BTX can be considered as a potential treatment in any situation involving inappropriate or exaggerated muscle contraction. Currently, the FDA has approved BTX-A (Botox) for treating glabellar lines, blepharospasm, strabismus, hemifacial spasm, cervical dystonia, and spasticity. With the addition of cosmetic applications to the FDA's approval list, the use of BTX has increased dramatically.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15158550 DOI: 10.1016/j.clindermatol.2003.12.030
Source DB: PubMed Journal: Clin Dermatol ISSN: 0738-081X Impact factor: 3.541